BWFA
TEVA icon

Baltimore-Washington Financial Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100
Closed -$5K – 305
2014
Q3 		$5K Buy
+100
New +$5.3K ﹤0.01% 245

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Baltimore-Washington Financial Advisors's TEVA Position: Q4 2014 in Review

Baltimore-Washington Financial Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 100 shares — an estimated $5K sold.

Baltimore-Washington Financial Advisors first reported a position in TEVA in Q3 2014 and held it in 1 quarter. The position peaked at $5K in Q3 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

  • Baltimore-Washington Financial Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Baltimore-Washington Financial Advisors sold 100 Teva Pharmaceuticals shares in Q4 2014, an estimated $5K.
  • Baltimore-Washington Financial Advisors first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Baltimore-Washington Financial Advisors's Teva Pharmaceuticals position peaked at $5K in Q3 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q4 2014, filed 21 Jan 2015.